These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 560794)

  • 21. Total neurochemical lesion of noradrenergic neurons of the locus ceruleus does not alter either naloxone-precipitated or spontaneous opiate withdrawal nor does it influence ability of clonidine to reverse opiate withdrawal.
    Caillé S; Espejo EF; Reneric JP; Cador M; Koob GF; Stinus L
    J Pharmacol Exp Ther; 1999 Aug; 290(2):881-92. PubMed ID: 10411605
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Brain levels of dextromethorphan and the intensity of opioid withdrawal in mice.
    Bisaga A; Kos T; Wójcikowski J; Daniel WA; Popik P
    Drug Alcohol Depend; 2008 May; 95(1-2):147-51. PubMed ID: 18328640
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dopaminergic-cholinergic interactions in naloxone-induced circling in morphine-dependent rats with nigral lesions.
    Iwamoto ET; Loh HH; Way EL
    Eur J Pharmacol; 1976 Jul; 38(1):39-54. PubMed ID: 986306
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Involvement of D2 dopamine receptors in the nucleus accumbens in the opiate withdrawal syndrome.
    Harris GC; Aston-Jones G
    Nature; 1994 Sep; 371(6493):155-7. PubMed ID: 7915401
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of L-745,870, a dopamine D4 receptor antagonist, on naloxone-induced morphine dependence in mice.
    Mamiya T; Matsumura T; Ukai M
    Ann N Y Acad Sci; 2004 Oct; 1025():424-9. PubMed ID: 15542745
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential roles of corticotropin-releasing factor receptor subtypes 1 and 2 in opiate withdrawal and in relapse to opiate dependence.
    Lu L; Liu D; Ceng X; Ma L
    Eur J Neurosci; 2000 Dec; 12(12):4398-404. PubMed ID: 11122350
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effects of selective dopamine D-1 and D-2 antagonists on the locomotor response and brain monoamine changes induced by naloxone-precipitated morphine withdrawal in guinea pigs.
    Brent PJ; Chahl LA
    Prog Clin Biol Res; 1990; 328():515-8. PubMed ID: 2406762
    [No Abstract]   [Full Text] [Related]  

  • 28. Differential effect of cannabinol and cannabidiol on THC-induced responses during abstinence in morphine-dependent rats.
    Hine B; Torrelio M; Gershon S
    Res Commun Chem Pathol Pharmacol; 1975 Sep; 12(1):185-8. PubMed ID: 1237925
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alteration of morphine withdrawal to naloxone by interferon.
    Dafny N; Zielinksi M; Reyes-Vazquez C
    Neuropeptides; 1983 Oct; 3(6):453-63. PubMed ID: 6420721
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of 1-phenyl-3-(2-thiazolyl)-2-thiourea, a dopamine beta-hydroxylase inhibitor on morphine analgesia, tolerance and physical dependence.
    Bhargava HN; Way EL
    J Pharmacol Exp Ther; 1974 Jul; 190(1):165-75. PubMed ID: 4858783
    [No Abstract]   [Full Text] [Related]  

  • 31. Antagonism of dopamine supersensitivity by estrogen: neurochemical studies in an animal model of tardive dyskinesia.
    Gordon JH; Diamond BI
    Biol Psychiatry; 1981 Apr; 16(4):365-71. PubMed ID: 7194695
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interferon as an endocoids candidate preventing and attenuating opiate addiction.
    Dafny N
    Prog Clin Biol Res; 1985; 192():269-76. PubMed ID: 4080713
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potentiation of apomorphine-induced rotational behaviour by naloxone.
    Quock RM; Welsh TB
    J Pharm Pharmacol; 1981 Feb; 33(2):111-3. PubMed ID: 6111591
    [No Abstract]   [Full Text] [Related]  

  • 34. Changes in the striatal adenylate cyclase activity following acute and chronic morphine treatment and during withdrawal.
    Puri SK; Volicer L; Cochin J
    J Neurochem; 1976 Dec; 27(6):1551-4. PubMed ID: 1033988
    [No Abstract]   [Full Text] [Related]  

  • 35. Haloperidol attenuation of morphine abstinence: synergistic effect of acute lithium administration.
    Hine B; Gershon S
    J Pharm Pharmacol; 1977 Apr; 29(4):238-40. PubMed ID: 17675
    [No Abstract]   [Full Text] [Related]  

  • 36. Chronic treatment with ascorbic acid inhibits the morphine withdrawal response in guinea-pigs.
    Johnston PA; Chahl LA
    Neurosci Lett; 1992 Jan; 135(1):23-7. PubMed ID: 1542433
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Three different types of alpha-interferons alter naloxone-induced abstinence in morphine-addicted rats.
    Dafny N; Reyes-Vazquez C
    Immunopharmacology; 1985 Feb; 9(1):13-7. PubMed ID: 4039302
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ethanol suppression of naloxone-induced withdrawal in morphine-dependent rats.
    Jones MA; Spratto GR
    Life Sci; 1977 May; 20(9):1549-55. PubMed ID: 559897
    [No Abstract]   [Full Text] [Related]  

  • 39. Brain dopamine and jumping behaviour in mice.
    Huang JT; Wajda I
    J Pharm Pharmacol; 1975 Dec; 27(12):940-2. PubMed ID: 2667
    [No Abstract]   [Full Text] [Related]  

  • 40. Dopaminergic involvement in withdrawal hypothermia and thermoregulatory behavior in morphine dependent rats.
    Cox B; Ary M; Lomax P
    Pharmacol Biochem Behav; 1976 Mar; 4(3):259-62. PubMed ID: 945579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.